Naive and in vitro-activated primary mouse CD8+ T cells retain in vivo immune responsiveness after electroporation-based CRISPR/Cas9 genetic engineering
P. Pfenninger, L. Yerly, J. Abe
This study shows that nucleofection-based CRISPR/Cas9 editing preserves in vivo immune function of naive CD8+ T cells but slightly impairs in vitro-activated cells, with varying gene product decay rates.
bioRxiv · Sep 14, 2021Immunology